| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics
|
Jun 15, 2026 | BUY |
Strong Buy
+9.0% avg upside
36 analysts
|
$120.00
32.74% Upside
|
+5.0% |
|
IMNM
Immunome
|
Jun 12, 2026 | BUY |
Strong Buy
+83.2% avg upside
16 analysts
|
$39.00
108.14% Upside
|
+0.8% |
|
RVMD
Revolution Medicines
|
Jun 08, 2026 | BUY |
Strong Buy
-12.2% avg upside
32 analysts
|
— | +6.2% |
|
ODTX
Odyssey Therapeutics, Inc.
|
Jun 02, 2026 | BUY |
Strong Buy
+67.8% avg upside
5 analysts
|
$26.00
36.36% Upside
|
· |
|
EIKN
Eikon Therapeutics, Inc.
|
May 31, 2026 | BUY |
Strong Buy
+147.2% avg upside
5 analysts
|
— | · |
|
TGTX
TG Therapeutics
|
May 27, 2026 | BUY |
Strong Buy
-34.3% avg upside
19 analysts
|
— | +28.9% |
|
IMVT
Immunovant
|
May 26, 2026 | BUY |
Strong Buy
+9.0% avg upside
24 analysts
|
$47.00
33.09% Upside
|
+2.6% |
|
ROIV
Roivant Sciences
|
May 26, 2026 | BUY |
Strong Buy
+2.5% avg upside
17 analysts
|
$40.00
27.29% Upside
|
+5.2% |
|
TARA
Protara Therapeutics
|
May 18, 2026 | BUY |
Strong Buy
+1153.9% avg upside
21 analysts
|
$26.00
553.34% Upside
|
-15.2% |
|
PTGX
Protagonist Therapeutics
|
May 13, 2026 | BUY |
Strong Buy
-22.1% avg upside
19 analysts
|
$113.00
0.21% Upside
|
+7.3% |
|
KYTX
Kyverna Therapeutics, Inc.
|
May 13, 2026 | BUY |
Strong Buy
+238.7% avg upside
7 analysts
|
$29.00
259.32% Upside
|
-25.4% |
|
NTLA
Intellia Therapeutics
|
May 13, 2026 | SELL |
Buy
+153.7% avg upside
37 analysts
|
$8.00
48.88% Downside
|
+15.2% |
|
PTCT
PTC Therapeutics
|
May 11, 2026 | BUY |
Buy
-1.4% avg upside
29 analysts
|
$89.00
12.63% Upside
|
+2.2% |
|
CGON
CG Oncology, Inc.
|
May 11, 2026 | BUY |
Strong Buy
+41.1% avg upside
17 analysts
|
$96.00
57.23% Upside
|
-11.9% |
|
GLUE
Monte Rosa Therapeutics
|
May 11, 2026 | BUY |
Strong Buy
+27.3% avg upside
14 analysts
|
$31.00
69.29% Upside
|
-9.6% |
|
XNCR
Xencor
|
May 11, 2026 | HOLD |
Strong Buy
+159.5% avg upside
27 analysts
|
$14.00
10.66% Upside
|
-11.9% |
|
ARWR
Arrowhead Pharmaceuticals
|
May 01, 2026 | BUY |
Strong Buy
-19.1% avg upside
26 analysts
|
$88.00
7.48% Upside
|
-0.4% |
|
ALLO
Allogene Therapeutics
|
Apr 16, 2026 | HOLD |
Strong Buy
+662.8% avg upside
28 analysts
|
— | -19.8% |
|
AAPG
Ascentage Pharma Group International Unsponsored ADR
|
Apr 15, 2026 | BUY |
Strong Buy
+156.4% avg upside
10 analysts
|
$46.00
168.70% Upside
|
-22.4% |
|
BEAM
Beam Therapeutics
|
Mar 25, 2026 | BUY |
Strong Buy
+51.4% avg upside
25 analysts
|
— | +27.2% |
|
EDIT
Editas Medicine
|
Mar 13, 2026 | SELL |
Buy
+420.3% avg upside
33 analysts
|
— | -8.4% |
|
ZYME
Zymeworks
|
Mar 03, 2026 | BUY |
Strong Buy
+40.3% avg upside
25 analysts
|
— | -8.0% |
|
CRSP
Crispr Therapeutics AG
|
Feb 13, 2026 | BUY |
Buy
+39.7% avg upside
41 analysts
|
$67.00
23.90% Upside
|
-2.0% |
|
PLRX
Pliant Therapeutics
|
Dec 04, 2025 | SELL |
Buy
+1820.7% avg upside
21 analysts
|
— | +6.1% |
|
OPK
Opko Health
|
Nov 20, 2025 | HOLD |
Strong Buy
+374.3% avg upside
12 analysts
|
— | -13.1% |
|
ABSI
AbSci
|
Oct 02, 2025 | BUY |
Strong Buy
+37.3% avg upside
18 analysts
|
— | +91.5% |
|
PGEN
Precigen
|
Aug 15, 2025 | HOLD |
Buy
+404.8% avg upside
11 analysts
|
— | +60.9% |
|
ADCT
ADC Therapeutics
|
Mar 21, 2025 | HOLD |
Buy
+450.4% avg upside
12 analysts
|
— | +139.8% |
|
BCAB
BioAtla
|
Sep 13, 2024 | HOLD |
Strong Buy
+2580.2% avg upside
13 analysts
|
— | -57.2% |
|
CHRS
Coherus Biosciences
|
Jul 15, 2024 | HOLD |
Buy
+748.3% avg upside
18 analysts
|
— | -48.5% |
|
MGX
Metagenomi, Inc.
|
May 02, 2024 | HOLD |
Strong Buy
+729.0% avg upside
7 analysts
|
$6.00
400.00% Upside
|
-73.9% |
|
ACET
Adicet Bio
|
Jun 01, 2023 | HOLD |
Strong Buy
+212.8% avg upside
14 analysts
|
$6.00
25.88% Downside
|
-72.1% |
|
SNTI
Senti Biosciences
|
Dec 16, 2022 | HOLD |
Strong Buy
+835.9% avg upside
7 analysts
|
— | -75.0% |
|
GOSS
Gossamer Bio
|
Dec 07, 2022 | SELL |
Buy
+4381.2% avg upside
17 analysts
|
— | +50.0% |
|
PRQR
ProQR
|
Apr 19, 2022 | BUY |
Strong Buy
+516.3% avg upside
18 analysts
|
$3.50
85.13% Upside
|
+193.4% |
|
BCRX
BioCryst
|
Apr 08, 2022 | BUY |
Strong Buy
+103.2% avg upside
24 analysts
|
$17.00
89.06% Upside
|
-21.9% |
|
LUCD
Lucid Diagnostics
|
Apr 04, 2022 | BUY |
Strong Buy
+350.9% avg upside
8 analysts
|
$12.00
1011.20% Upside
|
-62.2% |
|
ARCT
Arcturus Therapeutics
|
Mar 01, 2022 | BUY |
Buy
+291.8% avg upside
35 analysts
|
$86.00
1042.17% Upside
|
-26.2% |
|
EQ
Equillium
|
Nov 02, 2021 | BUY |
Strong Buy
+183.0% avg upside
14 analysts
|
$14.00
358.93% Upside
|
-73.3% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.